» Articles » PMID: 31276317

Structural Neuroimaging Differentiates Vulnerability from Disease Manifestation in Colombian Families with Huntington's Disease

Overview
Journal Brain Behav
Specialty Psychology
Date 2019 Jul 6
PMID 31276317
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The volume of the striatal structures has been associated with disease progression in individuals with Huntington's disease (HD) from North America, Europe, and Australia. However, it is not known whether the gray matter (GM) volume in the striatum is also sensitive in differentiating vulnerability from disease manifestation in HD families from a South-American region known to have high incidence of the disease. In addition, the association of enlarged brain perivascular spaces (PVS) with cognitive, behavioral, and motor symptoms of HD is unknown.

Materials And Methods: We have analyzed neuroimaging indicators of global atrophy, PVS burden, and GM tissue volume in the basal ganglia and thalami, in relation to behavioral, motor, and cognitive scores, in 15 HD patients with overt disease manifestation and 14 first-degree relatives not genetically tested, which represent a vulnerable group, from the region of Magdalena, Colombia.

Results: Poor fluid intelligence as per the Raven's Standard Progressive Matrices was associated with global brain atrophy (p = 0.002) and PVS burden (p ≤ 0.02) in HD patients, where the GM volume in all subcortical structures, with the exception of the right globus pallidus, was associated with motor or cognitive scores. Only the GM volume in the right putamen was associated with envy and MOCA scores (p = 0.008 and 0.015 respectively) in first-degree relatives.

Conclusion: Striatal GM volume, global brain atrophy and PVS burden may serve as differential indicators of disease manifestation in HD. The Raven's Standard Progressive Matrices could be a cognitive test worth to consider in the differentiation of vulnerability versus overt disease in HD.

Citing Articles

Brain Volumetric Analysis Using Artificial Intelligence Software in Premanifest Huntington's Disease Individuals from a Colombian Caribbean Population.

Rios-Anillo M, Ahmad M, Acosta-Lopez J, Cervantes-Henriquez M, Henao-Castano M, Morales-Moreno M Biomedicines. 2024; 12(10).

PMID: 39457479 PMC: 11504451. DOI: 10.3390/biomedicines12102166.


Mild cognitive impairment in Huntington's disease: challenges and outlooks.

Jellinger K J Neural Transm (Vienna). 2024; 131(4):289-304.

PMID: 38265518 DOI: 10.1007/s00702-024-02744-8.


Perivascular spaces relate to the course and cognition of Huntington's disease.

Li X, Xie J, Wang J, Bao Y, Dong Y, Gao B Transl Neurodegener. 2023; 12(1):30.

PMID: 37287074 PMC: 10245407. DOI: 10.1186/s40035-023-00359-9.


Fixel-Based Analysis Effectively Identifies White Matter Tract Degeneration in Huntington's Disease.

Oh S, Chen C, Wu Y, Hernandez M, Tsai C, Cheng J Front Neurosci. 2021; 15:711651.

PMID: 34588947 PMC: 8473742. DOI: 10.3389/fnins.2021.711651.


The Multi-Partner Consortium to Expand Dementia Research in Latin America (ReDLat): Driving Multicentric Research and Implementation Science.

Ibanez A, Yokoyama J, Possin K, Matallana D, Lopera F, Nitrini R Front Neurol. 2021; 12:631722.

PMID: 33776890 PMC: 7992978. DOI: 10.3389/fneur.2021.631722.


References
1.
Gonzalez-Castro V, Valdes Hernandez M, Chappell F, Armitage P, Makin S, Wardlaw J . Reliability of an automatic classifier for brain enlarged perivascular spaces burden and comparison with human performance. Clin Sci (Lond). 2017; 131(13):1465-1481. DOI: 10.1042/CS20170051. View

2.
McColgan P, Tabrizi S . Huntington's disease: a clinical review. Eur J Neurol. 2017; 25(1):24-34. DOI: 10.1111/ene.13413. View

3.
Pidgeon C, Rickards H . The pathophysiology and pharmacological treatment of Huntington disease. Behav Neurol. 2012; 26(4):245-53. PMC: 5214454. DOI: 10.3233/BEN-2012-120267. View

4.
Aylward E, Harrington D, Mills J, Nopoulos P, Ross C, Long J . Regional atrophy associated with cognitive and motor function in prodromal Huntington disease. J Huntingtons Dis. 2014; 2(4):477-89. PMC: 4412155. DOI: 10.3233/JHD-130076. View

5.
Wilkos E, Brown T, Slawinska K, Kucharska K . Social cognitive and neurocognitive deficits in inpatients with unilateral thalamic lesions - pilot study. Neuropsychiatr Dis Treat. 2015; 11:1031-8. PMC: 4401357. DOI: 10.2147/NDT.S78037. View